THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Clinical trials for THERAPY-RELATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new THERAPY-RELATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for THERAPY-RELATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a pill keep AML at bay? new study tests maintenance therapy after chemo
Disease control CompletedThis study looked at whether taking oral azacitidine (Onureg) as maintenance therapy can help older adults with acute myeloid leukemia (AML) stay in remission longer after treatment with CPX-351 chemotherapy. The study included 100 patients aged 65 and older who had achieved remi…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Promising drug combo targets tough leukemia in early trial
Disease control CompletedThis early-phase study tested a two-drug combination (pevonedistat plus decitabine) in 12 people with high-risk acute myeloid leukemia (AML), including those who had relapsed or couldn't tolerate standard chemo. The main goal was to find the safest dose and identify side effects.…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Tailoring chemo by genetics and health may boost survival in older AML patients
Disease control CompletedThis study tested whether matching chemotherapy intensity to a patient's genetic risk and overall health could improve outcomes for older adults (60+) with acute myeloid leukemia. 75 participants received either standard intensive or lower-intensity chemo based on their individua…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Nebraska • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental drug pair targets tough leukemias
Disease control CompletedThis early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Real-World italian study tracks vyxeos Liposomal's impact on Tough-to-Treat AML
Knowledge-focused CompletedThis study observed 113 adults in Italy with acute myeloid leukemia (AML) linked to prior cancer therapy or bone marrow problems. All participants received Vyxeos liposomal as part of their normal care. Researchers tracked how many achieved complete remission without detectable d…
Matched conditions: THERAPY-RELATED ACUTE MYELOID LEUKEMIA
Sponsor: Jazz Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC